New antibiotic candidate OMN6 tested against Drug-Resistant pneumonia

NCT ID NCT06087536

Recruiting now Disease control Sponsor: Omnix Medical Ltd Source: ClinicalTrials.gov ↗

First seen Mar 12, 2026 · Last updated May 24, 2026 · Updated 14 times

Summary

This study tests a new drug called OMN6 for adults with hospital-acquired pneumonia caused by Acinetobacter baumannii, a hard-to-treat bacteria. About 54 participants will receive either OMN6 or a placebo alongside standard antibiotics. The main goal is to check safety and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Omnix Medical Research Site
RECRUITING

Be’er Ya‘aqov, Israel
Omnix Medical Research Site
RECRUITING

Holon, Israel
Omnix Medical Research Site
RECRUITING

Petah Tikva, Israel
Omnix Medical Research Site
RECRUITING

Ramat Gan, Israel
Omnix Medical Research Site
RECRUITING

Rishon LeZiyyon, Israel

Conditions

Explore the condition pages connected to this study.

HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA